Lung Disease Clinical Trial
Official title:
Comparison of the Glidescope and Macintosh Laryngoscope for Double Lumen Endotracheal Tube Intubation
Verified date | February 2013 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
Patients undergoing chest surgery often require insertion of a breathing tube (double lumen tube) after they are unconscious. The double lumen tube enables the anaesthetist to ventilate (assist breathing) one lung at a time. The other lung is partially deflated to enable enough space for the surgeon to perform the procedure. The breathing tube is inserted with a laryngoscope (blade with a light at the end) so the vocal cords can be seen. This is standard medical practise. Two laryngoscopes are commonly used at Toronto General Hospital to insert the tube. The Macintosh laryngoscope has been is use for over 50 years and the Glidescope for over 10 years. Both devices have been extensively researched for single lumen tubes insertion and found to be very safe and effective. Research is limited to say which of the two laryngoscope is the most effective for double lumen tubes.
Status | Completed |
Enrollment | 70 |
Est. completion date | February 2013 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Population: planned elective lung surgery requiring general anaesthesia with a double lumen endotracheal intubation, signed informed patient consent. Exclusion Criteria: - Previous failed intubation, - history of difficult intubation or anticipated difficult intubation (2 risk factors of mallampati score 3 or greater, - incisor gap < 3.5cm, thyromental distance < 6.5cm, - reduced neck extension and flexion), - alternative method of intubation indicated eg rapid sequence intubation, - fibreoptic intubation, - contra-indication to a left double lumen tube eg endobronchial tumor, - significant deviation or compression of the trachea and bronchi., - contraindication to one lung ventilation eg severe hypoxia or pulmonary hypertension, - anticipated difficult bag mask ventilation, - symptomatic gastro-oesophageal reflux, - oral/pharyngeal/laryngeal carcinoma, - loose teeth, - allergy to rocuronium, BMI > 40. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Canada | Toronto General Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to intubation (laryngoscope or DLT inserted between patient's lips to DLT placement in the trachea and laryngoscope withdrawal) | Patients will be randomized to either MDL or GVL. If the first attempt fails to intubate within 2 minutes the anesthetist will remove the laryngoscope and provide mask ventilation. The second intubation attempt the anesthetist is encouraged to use the same randomized laryngoscope however, if the treating anesthetist feels a different device and technique will have a higher success rate they can perform that technique on the second attempt regardless of the randomized device. Anesthetists will complete a questionnaire after intubation. | Number of minutes (0-2) that is required to intubate will be recorded, if a 2nd attempt is required, duration to successfull intubation will be recorded in minutes. | No |
Secondary | Time to lung isolation, difficulty of the procedure, complication to the patients | Information about the procedure (times and complications) will be collected and documented by the study Anesthetist and questionnaires completed at the end of the 24hr postoperative period. Visits: patients will be followed up for a 24 hour period either on ward or by telephone if discharged, and assessed for sore throat, hoarseness, trauma to mouth and lips, dental damage and swallowing difficulties. | From the beginning of the operative procedure through to 24 hours postoperatively | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Recruiting |
NCT01450644 -
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
|
Phase 2 | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 |